Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype

References

• Spatz A, Cook MG, Elder DE, Piepkorn M, Ruiter DJ, Barnhill RL. Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer. 2003;39(13):1861–1865. doi:10.1016/S0959-8049(03)00325-3
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492. doi:10.3322/caac.21409
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) and beyond. Ann Surg Oncol. 2018;25(8):2105–2110. doi:10.1245/s10434-018-6513-7
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199. doi:10.1200/JCO.2009.23.4799
   PubMed Web of Science ®Google Scholar
• Haydu LE, Murali R, Bonenkamp JJ, Thompson JF, Scolyer RA, Scolyer RA. Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. Ann Surg. 2012;255(6):1165–1170. doi:10.1097/SLA.0b013e31824c4b0b
   PubMed Web of Science ®Google Scholar
• Portelli F, Galli F, Cattaneo L, et al. The prognostic impact of the extent of ulceration in patients with clinical stage I–II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI). Br J Dermatol. 2021;184(2):281–288. doi:10.1111/bjd.19120
   PubMed Web of Science ®Google Scholar
• Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American joint committee on cancer melanoma staging database. J Clin Oncol. 2011;29(16):2199. doi:10.1200/JCO.2010.31.5812
   PubMed Web of Science ®Google Scholar
• Gogas H, Eggermont AMM, Hauschild A, et al. Biomarkers in melanoma. Ann Oncol. 2009;20:vi8–vi13. doi:10.1093/annonc/mdp251
   PubMed Web of Science ®Google Scholar
• Spatz A, Stock N, Batist G, van Kempen LC. The biology of melanoma prognostic factors. Discov Med. 2010;10(50):87–93.
   PubMed Web of Science ®Google Scholar
• Newton‐Bishop JA, Davies JR, Latheef F, et al. 25‐Hydroxyvitamin D2/D3 levels and factors associated with systemic inflammation and melanoma survival in the leeds melanoma cohort. Int J Cancer. 2015;136(12):2890–2899. doi:10.1002/ijc.29334
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Spatz A, Lazar V, Robert C. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol. 2012;24(2):137–140. doi:10.1097/CCO.0b013e32834fcb0d
   PubMed Web of Science ®Google Scholar
• Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98(7):472–482. doi:10.1093/jnci/djj103
   PubMedGoogle Scholar
• Storr SJ, Safuan S, Mitra A, et al. Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. Mod Pathol. 2012;25(4):493–504. doi:10.1038/modpathol.2011.182
   PubMed Web of Science ®Google Scholar
• Jewell R, Elliott F, Laye J, et al. The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell Melanoma Res. 2015;28(1):94–104. doi:10.1111/pcmr.12315
   PubMed Web of Science ®Google Scholar
• Egger ME, Gilbert JE, Burton AL, et al. Lymphovascular invasion as a prognostic factor in melanoma. Am Surg. 2011;77(8):992–997. doi:10.1177/000313481107700816
   PubMed Web of Science ®Google Scholar
• Avilés-Izquierdo JA, Lázaro-Ochaita P. Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain. Clin Transl Oncol. 2012;14(3):237–240. doi:10.1007/s12094-012-0790-6
   PubMed Web of Science ®Google Scholar
• Scoggins CR, Ross MI, Reintgen DS, et al. Gender-related differences in outcome for melanoma patients. Ann Surg. 2006;243(5):693. doi:10.1097/01.sla.0000216771.81362.6b
   PubMed Web of Science ®Google Scholar
• Balch CM, Wilkerson JA, Murad TM, Soong S, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45(12):3012–3017. doi:10.1002/1097-0142(19800615)45:12<3012::AID-CNCR2820451223>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• McGovern VJ, Shaw HM, Milton GW, McCarthy WH. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology. 1982;6(4):399–407. doi:10.1111/j.1365-2559.1982.tb02737.x
   PubMed Web of Science ®Google Scholar
• Callender GG, Egger ME, Burton AL, et al. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker. Am J Surg. 2011;202(6):659–665. doi:10.1016/j.amjsurg.2011.06.048
   PubMed Web of Science ®Google Scholar
• Boczar D, Sisti A, Restrepo DJ, et al. National analysis of patients with ulcerated melanoma in the United States. Anticancer Res. 2020;40(2):1055–1058. doi:10.21873/anticanres.14042
   PubMed Web of Science ®Google Scholar
• Davies J, Muralidhar S, Randerson‐Moor J, et al. Ulcerated melanoma: systems biology evidence of inflammatory imbalance towards pro‐tumourigenicity. Pigment Cell Melanoma Res. 2022;35(2):252–267. doi:10.1111/pcmr.13023
   PubMed Web of Science ®Google Scholar
• von Schuckmann LA, Smith D, Hughes MCB, et al. Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma. J Invest Dermatol. 2017;137(12):2599–2605. doi:10.1016/j.jid.2017.07.836
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615–1622. doi:10.1001/jama.279.20.1615
   PubMed Web of Science ®Google Scholar
• Bonovas S, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, Sitaras NM. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol. 2010;25(1):29–35. doi:10.1007/s10654-009-9396-x
   PubMed Web of Science ®Google Scholar
• Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case–control study. J Invest Dermatol. 2011;131(7):1460–1468. doi:10.1038/jid.2011.58
   PubMed Web of Science ®Google Scholar
• Jagtap D, Rosenberg CA, Martin LW, et al. Prospective analysis of association between use of statins and melanoma risk in the women’s health initiative. Cancer. 2012;118(20):5124–5131. doi:10.1002/cncr.27497
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi P, Yibulayin F, Feng L, Zhang H, Wushou A. Spindle cell melanoma: incidence and survival, 1973–2017. Oncol Lett. 2018;16(4):5091–5099. doi:10.3892/ol.2018.9247
   PubMed Web of Science ®Google Scholar
• Lade‐Keller J, Riber‐Hansen R, Guldberg P, Schmidt H, Hamilton‐Dutoit SJ, Steiniche T. E‐to N‐cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression. Br J Dermatol. 2013;169(3):618–628. doi:10.1111/bjd.12426
   PubMed Web of Science ®Google Scholar
• Måsbäck A, Westerdahl J, Ingvar C, Olsson H, Jonsson N. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985: prognostic factors and histologic correlations. Cancer. 1997;79(2):275–283. doi:10.1002/(SICI)1097-0142(19970115)79:2<275::AID-CNCR11>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Wei X, Wu D, Chen Y, et al. Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study. Br J Dermatol. 2022;186:977–987. doi:10.1111/bjd.21026
   PubMed Web of Science ®Google Scholar
• Vlaykova T, Muhonen T, Hahka‐Kemppinen M, Pyrhönen S, Jekunen A. Vascularity and prognosis of metastatic melanoma. Int J Cancer. 1997;74(3):326–329. doi:10.1002/(SICI)1097-0215(19970620)74:3<326::AID-IJC16>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Pisacane AM, Picciotto F, Risio M. CD31 and CD34 expression as immunohistochemical markers of endothelial transdifferentiation in human cutaneous melanoma. Anal Cell Pathol. 2007;29(1):59–66. doi:10.1155/2007/486579
   Google Scholar
• Li X, Karras P, Torres R, et al. Disseminated melanoma cells transdifferentiate into endothelial cells in intravascular niches at metastatic sites. Cell Rep. 2020;31(11):107765. doi:10.1016/j.celrep.2020.107765
   PubMed Web of Science ®Google Scholar
• Barnhill R, Dy K, Lugassy C. Angiotropism in cutaneous melanoma: a prognostic factor strongly predicting risk for metastasis. J Invest Dermatol. 2002;119(3):705–706. doi:10.1046/j.1523-1747.2002.01871.x
   PubMed Web of Science ®Google Scholar
• Lugassy C, Vernon SE, Busam K, et al. Angiotropism of human melanoma: studies involving in transit and other cutaneous metastases and the chicken chorioallantoic membrane: implications for extravascular melanoma invasion and metastasis. Am J Dermatopathol. 2006;28(3):187. doi:10.1097/00000372-200606000-00001
   PubMed Web of Science ®Google Scholar
• Lugassy C, Wadehra M, Li X, et al. Pilot study on “pericytic mimicry” and potential embryonic/stem cell properties of angiotropic melanoma cells interacting with the abluminal vascular surface. Cancer Microenviron. 2013;6(1):19–29. doi:10.1007/s12307-012-0128-5
   PubMedGoogle Scholar
• Bald T, Quast T, Landsberg J, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. 2014;507(7490):109–113. doi:10.1038/nature13111
   PubMed Web of Science ®Google Scholar
• Bønnelykke-Behrndtz ML, Steiniche T, Nørgaard P, et al. Loss of E-cadherin as part of a migratory phenotype in melanoma is associated with ulceration. Am J Dermatopathol. 2017;39(9):672–678. doi:10.1097/DAD.0000000000000750
   PubMed Web of Science ®Google Scholar
• Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010;33(5):657–670. doi:10.1016/j.immuni.2010.11.011
   PubMed Web of Science ®Google Scholar
• Rose AE, Christos PJ, Lackaye D, et al. Clinical relevance of detection of lymphovascular invasion in primary melanoma using endothelial markers D2-40 and CD34. Am J Surg Pathol. 2011;35(10):1441. doi:10.1097/PAS.0b013e31822573f5
   PubMed Web of Science ®Google Scholar
• Sahni D, Robson A, Orchard G, Szydlo R. The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status. J Clin Pathol. 2005;58(7):715–721. doi:10.1136/jcp.2004.020123
   PubMed Web of Science ®Google Scholar
• Massi D, Puig S, Franchi A, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case–control study. J Clin Pathol. 2006;59(2):166–173. doi:10.1136/jcp.2005.028431
   PubMed Web of Science ®Google Scholar
• Vihinen P, Koskivuo I, Syrjänen K, Tervahartiala T, Sorsa T, Pyrhönen S. Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res. 2008;18(4):268–273. doi:10.1097/CMR.0b013e3283090031
   PubMed Web of Science ®Google Scholar
• Nikkola J, Vihinen P, Vlaykova T, Hahka‐Kemppinen M, Kähäri V, Pyrhönen S. High expression levels of collagenase‐1 and stromelysin‐1 correlate with shorter disease‐free survival in human metastatic melanoma. Int J Cancer. 2002;97(4):432–438. doi:10.1002/ijc.1636
   PubMed Web of Science ®Google Scholar
• Liu H, Wei Q, Gershenwald JE, et al. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res. 2012;22(2):169. doi:10.1097/CMR.0b013e32834fc46b
   PubMed Web of Science ®Google Scholar
• Petrova YI, Schecterson L, Gumbiner BM. Roles for E-cadherin cell surface regulation in cancer. Mol Biol Cell. 2016;27(21):3233–3244. doi:10.1091/mbc.E16-01-0058
   PubMed Web of Science ®Google Scholar
• Mitchell B, Leone DA, Feller JK, Yang S, Mahalingam M. BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin? Hum Pathol. 2016;52:19–27. doi:10.1016/j.humpath.2015.12.030
   PubMed Web of Science ®Google Scholar
• Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V, Li G. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol. 2013;169(2):320–328. doi:10.1111/bjd.12351
   PubMed Web of Science ®Google Scholar
• Falkenius J, Keskitalo J, Kanter L, et al. A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma. Acta Oncologica. 2022;61(1):14–21. doi:10.1080/0284186X.2021.1989719
   PubMed Web of Science ®Google Scholar
• Christofyllakis K, Pföhler C, Bewarder M, et al. Adjuvant therapy of high-risk (Stages IIC–IV) malignant melanoma in the post interferon-alpha era: a systematic review and meta-analysis. Front Oncol. 2021;10:3481. doi:10.3389/fonc.2020.637161
   Web of Science ®Google Scholar
• Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003;22(20):3113–3122. doi:10.1038/sj.onc.1206451
   PubMed Web of Science ®Google Scholar
• Cabrita R, Mitra S, Sanna A, et al. The role of PTEN loss in immune escape, melanoma prognosis and therapy response. Cancers. 2020;12(3):742. doi:10.3390/cancers12030742
   PubMed Web of Science ®Google Scholar
• Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res. 2005;11(14):5153–5157. doi:10.1158/1078-0432.CCR-05-0397
   PubMed Web of Science ®Google Scholar
• Slipicevic A, Holm R, Nguyen MTP, Bøhler PJ, Davidson B, Flørenes VA. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol. 2005;124(4):528–536. doi:10.1309/YT58WWMTA6YR1PRV
   PubMed Web of Science ®Google Scholar
• de Unamuno Bustos B, Murria Estal R, Pérez Simó G, et al. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma. Br J Dermatol. 2018;179(2):394–404. doi:10.1111/bjd.16254
   PubMed Web of Science ®Google Scholar
• Verver D, Poirier-Colame V, Tomasic G, et al. Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. OncoImmunology. 2019;8(11):e1660121. doi:10.1080/2162402X.2019.1660121
   PubMed Web of Science ®Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301–1309. doi:10.1038/nm.3708
   PubMed Web of Science ®Google Scholar
• Martinoli C, Gandini S, Luise C, et al. Maspin expression and melanoma progression: a matter of sub-cellular localization. Mod Pathol. 2014;27(3):412–419. doi:10.1038/modpathol.2013.157
   PubMed Web of Science ®Google Scholar
• Bezrookove V, Nosrati M, Miller JR, et al. Role of elevated PHIP copy number as a prognostic and progression marker for cutaneous melanoma. Clin Cancer Res. 2018;24(17):4119–4125. doi:10.1158/1078-0432.CCR-18-0791
   PubMed Web of Science ®Google Scholar
• Bezrookove V, de Semir D, Nosrati M, et al. Prognostic impact of PHIP copy number in melanoma: linkage to ulceration. J Invest Dermatol. 2014;134(3):783–790. doi:10.1038/jid.2013.369
   PubMed Web of Science ®Google Scholar
• Gironi LC, Colombo E, Pasini B, et al. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers. Arch Dermatol Res. 2018;310(10):769–784. doi:10.1007/s00403-018-1866-0
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Tuominen R, Olsson H, Hansson J, Höiom V. Cancer risks and survival in patients with multiple primary melanomas: association with family history of melanoma and germline CDKN2A mutation status. J Am Acad Dermatol. 2017;77(5):893–901. doi:10.1016/j.jaad.2017.05.050
   PubMed Web of Science ®Google Scholar
• Chen G, Cheng Y, Zhang Z, Martinka M, Li G. Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival. PLoS One. 2011;6(2):e17578. doi:10.1371/journal.pone.0017578
   PubMed Web of Science ®Google Scholar
• Miracco C, Cevenini G, Franchi A, et al. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Hum Pathol. 2010;41(4):503–512. doi:10.1016/j.humpath.2009.09.004
   PubMed Web of Science ®Google Scholar
• Lee KH, Suh HY, Lee MW, Lee WJ, Chang SE. Prognostic significance of epidermal growth factor receptor expression in distant metastatic melanoma from primary cutaneous melanoma. Ann Dermatol. 2021;33(5):432. doi:10.5021/ad.2021.33.5.432
   PubMed Web of Science ®Google Scholar
• Katunaric M, Jurišic D, Petkovic M, Grahovac M, Grahovac B, Zamolo G. EGFR and cyclin D1 in nodular melanoma: correlation with pathohistological parameters and overall survival. Melanoma Res. 2014;24(6):584–591. doi:10.1097/CMR.0000000000000123
   PubMed Web of Science ®Google Scholar
• Papadodima O, Kontogianni G, Piroti G, Maglogiannis I, Chatziioannou A. Genomics of cutaneous melanoma: focus on next-generation sequencing approaches and bioinformatics. J Transl Genet Genom. 2019;3:7.
   Google Scholar
• de Unamuno Bustos B, Murria Estal R, Pérez Simó G, et al. Towards personalized medicine in melanoma: implementation of a clinical next-generation sequencing panel. Sci Rep. 2017;7(1):1–11. doi:10.1038/s41598-017-00606-w
   PubMed Web of Science ®Google Scholar
• Lee JJ, Sholl LM, Lindeman NI, et al. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. Clin Epigenetics. 2015;7(1):1–17. doi:10.1186/s13148-015-0091-3
   PubMed Web of Science ®Google Scholar
• Valentini V, Zelli V, Gaggiano E, et al. miRNAs as potential prognostic biomarkers for metastasis in thin and thick primary cutaneous melanomas. Anticancer Res. 2019;39(8):4085–4093. doi:10.21873/anticanres.13566
   PubMed Web of Science ®Google Scholar
• Babapoor S, Wu R, Kozubek J, Auidi D, Grant-Kels JM, Dadras SS. Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. Lab Invest. 2017;97(6):636–648. doi:10.1038/labinvest.2017.5
   PubMed Web of Science ®Google Scholar
• Lin N, Zhou Y, Lian X, Tu Y. Expression of microRNA-106b and its clinical significance in cutaneous melanoma. Genet Mol Res. 2015;14(4):16379–16385. doi:10.4238/2015.December.9.6
   PubMed Web of Science ®Google Scholar
• DiVincenzo MJ, Ren C, Suarez-Kelly L, et al. Determination of the expression patterns and functional implications of microRNAs in ulcerated cutaneous melanoma. Cancer Res. 2020;80:3696.
   Web of Science ®Google Scholar
• DiVincenzo MJ, Barricklow Z, Schwarz E, et al. Loss of miR-1469 expression mediates melanoma cell migration and invasion. PLoS One. 2021;16(9):e0256629. doi:10.1371/journal.pone.0256629
   PubMed Web of Science ®Google Scholar
• de Moll EH, Fu Y, Qian Y, et al. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunol Immunother. 2015;64(9):1193–1203. doi:10.1007/s00262-015-1726-0
   PubMed Web of Science ®Google Scholar
• Elliott B, Scolyer RA, Suciu S, et al. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res. 2007;13(13):3825–3830. doi:10.1158/1078-0432.CCR-07-0358
   PubMed Web of Science ®Google Scholar
• Dyduch G, Tyrak KE, Glajcar A, Szpor J, Okoń K. CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma. Adv Dermatol Allergol. 2017;34(3):233. doi:10.5114/ada.2017.67845
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19(2):577–583. doi:10.1200/JCO.2001.19.2.577
   PubMed Web of Science ®Google Scholar
• Vihinen PP, Pyrhönen SO, Kähäri VM. New prognostic factors and developing therapy of cutaneous melanoma. Ann Med. 2003;35(2):66–78. doi:10.1080/07853890310009980
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810–3818. doi:10.1200/JCO.2011.41.3799
   PubMed Web of Science ®Google Scholar
• Abdolvahab MH, Darvishi B, Zarei M, Majidzadeh-A K, Farahmand L. Interferons: role in cancer therapy. Immunotherapy. 2020;12(11):833–855. doi:10.2217/imt-2019-0217
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012;48(2):218–225. doi:10.1016/j.ejca.2011.09.028
   PubMed Web of Science ®Google Scholar
• Egger ME, Scoggins CR, McMasters KM. The sunbelt melanoma trial. Ann Surg Oncol. 2020;27(1):28–34. doi:10.1245/s10434-019-07828-4
   PubMed Web of Science ®Google Scholar
• Baurain J, Stas M, Hammouch F, et al. Association of primary melanoma ulceration and clinical benefit of adjuvant vaccination with tumor-specific antigenic peptides. J Clin Oncol. 2009;27(15_suppl):3022. doi:10.1200/jco.2009.27.15_suppl.3022
   Web of Science ®Google Scholar
• Slingluff CL, Lewis KD, Andtbacka R, et al. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. J Immunother Cancer. 2021;9:10. doi:10.1136/jitc-2021-003272
   Web of Science ®Google Scholar
• Rossfeld K, Hade EM, Gangi A, et al. Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics. Int J Surg Oncol. 2017;2(9):e43. doi:10.1097/IJ9.0000000000000043
   Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855. doi:10.1056/NEJMoa1611299
   PubMed Web of Science ®Google Scholar